Articles by David Braun, MD, PhD
Dr. Braun shares insights on updates to the NCCN guidelines for RCC, highlighting how they could impact clinical practice.
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
Drs. Braun and Beckermann discuss the evolving significance of sarcomatoid histology in guiding treatment decisions for RCC.
Drs. McKay and Braun wrap up their discussion with comments on which novel therapies hold the most promise in advanced RCC.
Drs. McKay and Braun share their strategy for strategy for patient selection in the clinic, including first- and second-line.
Drs. McKay and Braun highlights novel RCC biomarkers being developed, including imaging-, pathology-, and blood-based ones.
Dr. McKay speaks with Dr. Braun on the current biomarker landscape for RCC and how biomarkers have shaped treatment.
David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.